Indication
Retinal Diseases
5 clinical trials
5 products
Product
MCO-010Clinical trial
A Phase 2b Randomized, Double-Masked, Sham-Controlled, Study to Evaluate the Efficacy and Safety of Intravitreal Injection of MCO-010 Optogenetic Therapy in Adults With Retinitis Pigmentosa [RESTORE]Status: Completed, Estimated PCD: 2023-02-27
Clinical trial
Long Term Follow-up for Subjects Who Previously Participated in the NTXMCO-002 RESTORE StudyStatus: , Estimated PCD: 2027-07-01
Product
AAV OPTIRPE65Clinical trial
Long-term Follow-up Study of Participants Following an Open Label, Multi-centre, Phase I/II Dose Escalation Trial of an Adeno-associated Virus Vector (AAV2/5-OPTIRPE65) for Gene Therapy of Adults and Children With Retinal Dystrophy Owing to Defects in RPE65 (LCA2)Status: Completed, Estimated PCD: 2023-07-01
Clinical trial
A Phase 2b, Prospective, Multicenter, Randomized, Double-Masked, Active-Controlled Study to Assess the Efficacy and Safety of Repeat Intravitreal Injections of Foselutoclax (UBX1325) in Patients With Diabetic Macular EdemaStatus: Recruiting, Estimated PCD: 2025-03-01
Product
AfliberceptProduct
foselutoclaxClinical trial
Phase I Trial of Ocular Subretinal Injection of a Recombinant Adeno-Associated Virus (rAAV2-CBSB-hRPE65) Gene Vector to Patients With Retinal Disease Due to RPE65 Mutations (Clinical Trials of Gene Therapy for Leber Congenital Amaurosis)Status: Active (not recruiting), Estimated PCD: 2026-06-01
Product
rAAV2-CBSB-hRPE65